Zai Lab Limited (NASDAQ:ZLAB) CEO Sells $122,587.24 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 7,013 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $17.48, for a total transaction of $122,587.24. Following the completion of the transaction, the chief executive officer now owns 1,081,910 shares of the company’s stock, valued at approximately $18,911,786.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ying Du also recently made the following trade(s):

• On Wednesday, June 26th, Ying Du sold 23,939 shares of Zai Lab stock. The stock was sold at an average price of $17.90, for a total transaction of $428,508.10.

Zai Lab Trading Down 0.9 %

Zai Lab stock opened at $17.22 on Friday. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $32.60. The firm’s fifty day moving average is $18.51 and its 200 day moving average is $19.86.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The company had revenue of $87.15 million for the quarter, compared to the consensus estimate of $77.07 million. During the same quarter in the previous year, the company earned ($0.51) EPS. As a group, equities research analysts predict that Zai Lab Limited will post -2.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its position in shares of Zai Lab by 1,923.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,550 shares of the company’s stock valued at $70,000 after acquiring an additional 2,424 shares during the period. BNP Paribas Financial Markets raised its holdings in Zai Lab by 51.2% during the first quarter. BNP Paribas Financial Markets now owns 2,671 shares of the company’s stock worth $43,000 after buying an additional 904 shares during the last quarter. Headlands Technologies LLC acquired a new position in Zai Lab during the first quarter worth $64,000. Sectoral Asset Management Inc. raised its holdings in Zai Lab by 33.3% during the fourth quarter. Sectoral Asset Management Inc. now owns 4,000 shares of the company’s stock worth $109,000 after buying an additional 1,000 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Zai Lab during the fourth quarter worth $116,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $64.57.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.